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Abstract 
Background: Lactobacillus spp. dominating the vaginal microbiota of healthy women contribute to the prevention 
of urogenital and sexually transmitted infections. Their protective role in the vagina can be mediated by Lactobacil-
lus cells themselves, metabolites or bacterial components, able to interfere with pathogen adhesion and infectivity. 
Vulvovaginal candidiasis (VVC) is a common genital infection, caused by the overgrowth of opportunistic Candida 
spp. including C. albicans, C. glabrata, C. krusei and C. tropicalis. Azole antifungal drugs are not always efficient in resolv‑
ing VVC and preventing recurrent infections, thus alternative anti‑Candida agents based on vaginal probiotics have 
gained more importance. The present work aims to chemically characterize the biosurfactant (BS) isolated from a 
vaginal Lactobacillus crispatus strain, L. crispatus BC1, and to investigate its safety and antiadhesive/antimicrobial activ‑
ity against Candida spp., employing in vitro and in vivo assays.
Results: BS isolated from vaginal L. crispatus BC1 was characterised as non‑homogeneous lipopeptide molecules 
with a critical micellar concentration value of 2 mg/mL, and good emulsification and mucoadhesive properties. At 
1.25 mg/mL, the BS was not cytotoxic and reduced Candida strains’ ability to adhere to human cervical epithelial cells, 
mainly by exclusion mechanism. Moreover, intravaginal (i.va.) inoculation of BS in a murine experimental model was 
safe and did not perturb vaginal cytology, histology and cultivable vaginal microbiota. In the case of i.va. challenge of 
mice with C. albicans, BS was able to reduce leukocyte influx.
Conclusions: These results indicate that BS from vaginal L. crispatus BC1 is able to interfere with Candida adhesion 
in vitro and in vivo, and suggest its potential as a preventive agent to reduce mucosal damage occasioned by Candida 
during VVC.
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Background
Candida species are part of the mucosal microbiota of 
the gastrointestinal and genitourinary tracts of most 
healthy women. In certain conditions, these yeasts can 
become opportunistic pathogens and overgrow on the 
vulvovaginal mucosa, originating symptomatic vul-
vovaginal candidiasis (VVC). Until some years ago, 
the species most commonly detected in VVC was C. 
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albicans. However, during the last two decades, with 
the development of more accurate molecular diagnos-
tics, infections by different species (i.e. C. glabrata, C. 
krusei and C. tropicalis) have emerged producing an 
increase in causative species of VVC [1]. Antifungal 
azoles are usually applied for VVC treatment; however, 
the prolonged exposition to these drugs can generate 
high resistance pressure, thus promoting the appear-
ance of azole-resistant Candida strains. Thus, the 
search for anti-Candida agents with new pharmaco-
logical targets is a priority for effective prevention and 
treatment of these types of infections [2].
Lactobacilli are the predominant microorganisms in 
the vaginal microbiota of healthy women that contribute 
to preventing urogenital and sexually transmitted infec-
tions [3–5]. The protective role in the vagina is exerted 
through different mechanisms including: adhesion and 
permanence on the epithelium (promoted by biofilm for-
mation), competitive exclusion against pathogens, pro-
duction of antimicrobial compounds and/or modulation 
of the host’s immune response [3, 6–9]. In this scenario, 
probiotics or pharmaceuticals containing lactobacilli or 
their derivatives represent a novel strategy to reconsti-
tute the vaginal microbiota and prevent/treat urogeni-
tal infections [10, 11]. The World Health Organization 
defines probiotics as “live microorganisms which, when 
administered in adequate amounts, confer a health ben-
efit on the host” [12, 13]. Pharmabiotics include “live or 
dead microorganisms, as well as microbial components 
and metabolites that can interact beneficially with the 
host” [14].
Different scientists have shown that specific cell surface 
components of lactobacilli and some metabolites con-
tribute to their beneficial effects [15–19]. Biosurfactants 
(BS) are amphiphilic compounds produced by micro-
organisms, anchored on the surface or secreted to the 
outside, with outstanding surface and emulsifying prop-
erties [20]. These molecules, mainly secondary metabo-
lites, exert critical functions in the survival of producer 
microorganisms by facilitating the transport of nutrients, 
interfering with microorganism–host interactions and 
“quorum sensing”, or acting as antimicrobial, anti-adhe-
sive and anti-biofilms agents [15, 16, 21, 22]. Differently 
from synthetic surfactants, BS are considered “green” 
compounds because of their natural origin, biodegrada-
bility and low toxicity [23], which support their use in 
medicine. Among pharmaceutical applications, BS anti-
bacterial, antiviral, antifungal and anticancer effects have 
been reported [21, 24, 25]. Recently, two studies have 
been focused on the formulation of BS, isolated from a 
vaginal L. gasseri strain, inside liposomes active against 
Candida and methicillin resistant Staphylococcus aureus 
strains [26, 27].
In the perspective to contribute to the understanding 
of the biological role of lactobacilli in the vaginal niche as 
well as to promote the application of their isolated com-
ponents, the present work aims to chemically character-
ize the BS isolated from a vaginal Lactobacillus crispatus 
strain, and to investigate its cytotoxicity and antiadhesive 




Lactobacillus crispatus BC1, originally isolated from 
the vaginal swab of a healthy premenopausal volunteer 
following the protocol approved by the Ethics Commit-
tee of the University of Bologna (52/2014/U/Tess) and 
selected for its antimicrobial properties [28], was used 
in this study. The strain was cultured in de Man, Rogosa 
and Sharpe (MRS) (Beckton, Dickinson and Co., Milan, 
Italy) broth supplemented with 0.05% l-cysteine (Sigma-
Aldrich, Milan, Italy), at 37 °C for 24 h in anaerobic jars 
containing GasPak EZ (Beckton, Dickinson and Co.).
Six clinical isolates of Candida spp. (C. albicans 1, C. 
albicans 2, C. albicans 4, C. tropicalis, C. krusei and C. 
glabrata), belonging to a collection of yeasts isolated 
from vaginal swabs of premenopausal, VVC affected-
women during routine diagnostic procedures at the 
Microbiology Laboratory of Sant’Orsola-Malpighi Uni-
versity Hospital of Bologna, were used in the present 
study [28]. Candida strains were grown aerobically 
at 35  °C for 16  h in Sabouraud dextrose agar (Beckton, 
Dickinson and Co.).
Isolation of BS from L. crispatus BC1
The cell-bound BS was isolated according to the method 
previously published by Abruzzo et  al. [26]. Briefly, 
100 mL of an overnight culture of L. crispatus BC1 were 
inoculated in 900 mL of MRS broth and allowed to grow 
for 24  h in anaerobic jars containing GasPak EZ. Then, 
the cell pellet was harvested by centrifugation (10.000×g, 
10  min), washed twice in sterile water, before being re-
suspended in 300 mL of sterile PBS (2.38 g/L  Na2HPO4, 
0.19  g/L  KH2PO4 and 8  g/L NaCl) and gently stirred at 
room temperature for 2  h to release the cell-bound BS. 
Subsequently the suspension was centrifuged and the 
supernatant filtered through a 0.22  μm pore size filter 
(PES 0.22 μm syringe filters, VWR International, Milan, 
Italy). Cell-free supernatant was then subjected to dialy-
sis against demineralized water in a Cellu-Sep© mem-
brane (molecular weight cut-off 6000–8000 Da; Spectra/
Por 2 dialysis membrane, Spectrum Laboratories Inc., 
Rancho Dominguez, CA) for 24 h at room temperature, 
and freeze-dried at 0.01 atm and − 45  °C (Christ Freeze 
Dryer ALPHA 1–2, Milan, Italy). This procedure allowed 
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to obtain about 60  mg of lyophilized BS crude multi-
component product (defined as BS) from 1 L of L. crispa-
tus BC1 culture.
Chemical characterization of BS
Fourier transformed infrared spectroscopy (FT‑IR)
Fourier transformed infrared spectroscopy analyses were 
conducted with a Jasco FT-IR 4100 spectrophotometer 
(Jasco, Lecco, Italy) in order to determine the functional 
groups of the isolated BS. Freeze-dried BS was gently 
triturated with KBr powder (Sigma-Aldrich) with BS/
KBr weight ratio 1:10 and then pressed using a hydraulic 
press at a pressure of 100 tons for 5  min. The disc was 
placed in the sample holder and scanned between 4000 
and 450 cm−1.
Mass spectrometric analysis
BS characterisation by mass spectrometry (MS) assays 
was carried out according to the previously published 
method by Abruzzo et  al. [26], by means of a Waters 
(Milford, MA, USA) Micromass Quattro Micro triple 
quadrupole (QqQ) mass spectrometer interfaced with an 
electrospray ion source operating in positive and nega-
tive ionisation modes (ESI+/ESI−). BS was dissolved 
in ultrapure water and diluted with the same solvent to 
reach the concentration of 10 μg/mL. BS solutions were 
directly infused by means of a Harvard Apparatus (Hol-
liston, MA) 11 Plus programmable syringe pump into the 
ESI source, at a flowrate of 10  μL/min. Data processing 
was performed using Waters MassLynx 4.1 software. Full 
scan MS spectra (scan duration: 500 ms) were acquired 
by applying MS parameters as follows: capillary voltage 
was set at 3.0 kV, while cone voltage was tested within a 
range of 15–100 V in order to test variation in BS ionis-
ability and possible fragmentation patterns; source and 
desolvation temperatures were kept at 120 °C and 150 °C, 
respectively; cone gas  (N2) flow was set to 50 L/h while 
desolvation gas  (N2) flow was 200 L/h.
Surface‑activity determination and critical micelle 
concentration of BS
The critical micellar concentration (CMC) of BS was 
measured by the ring method using a tensiometer 
(K8600E Krüss GmbH, Hamburg, Germany) equipped 
with a 1.9 cm platinum ring [26]. Surface tension (dyne/
cm) of BS aqueous solutions at different concentrations 
(0.03–8.0  mg/mL) was measured at room temperature. 
The concentration at which surfactant molecules aggre-
gate and form micelles in aqueous environment (CMC) 
was determined by plotting the surface tension as a func-
tion of the logarithm of BS concentration. CMC is rep-
resented as the point at which the baseline of minimal 
surface tension intersects the slope where surface tension 
shows a linear decline.
To evaluate BS stability in a pH range representative 
of the human vaginal environment in physiological and 
pathological conditions [4], BS was dissolved (1.25  mg/
mL) in aqueous solutions adjusted to pH 3, 4, 5 and 6 
with 0.1 M HCl, and the surface tension was determined 
as described above.
Emulsification properties of BS
For this study, 1 mL of BS solution (1.25 mg/mL), 4 mL of 
water and 6 mL of olive oil, sunflower oil or wheat germ 
oil (Polichimica, Bologna, Italy) were vigorously shaken 
in graduated glass test tubes for 2  min to obtain maxi-
mum emulsification [29]. After 24  h, the height of the 
emulsion was measured and emulsification index (EI24) 
was calculated using the following equation:
Water and Tween 80 (Fluka, Milan, Italy) at a concen-
tration of 1  mg/mL were used as negative and positive 
controls, respectively.
Mucoadhesive properties
Mucoadhesive properties were determined through tur-
bidimetric analysis of a suspension containing mucin and 
BS [30]. Mucin (Type II: crude, from porcine stomach, 
Sigma-Aldrich) was dispersed in water (0.08% w/v) and 
after 24  h the dispersion was centrifuged at 7500  rpm 
(GS-15R Centrifuge, Beckman Coulter, Milan, Italy) for 
20 min in order to discharge the excess of mucin. Subse-
quently, the isolated mucin supernatant and a BS solution 
(1.25  mg/mL) were mixed (1:3 v/v) for 3  h. The turbid-
ity of the mixture was measured at 650 nm (UV–Visible 
Spectrophotometer, Shimadzu Corporation, Australia) 
and compared to the controls (mucin supernatant and BS 
solution without mucin).
Cytotoxicity of BS on human cervical cells (HeLa)
The impact of BS on the proliferation of HeLa cells was 
evaluated by colorimetric assay with 3-(45-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazol (MTT) [31]. HeLa cells 
were maintained in Dulbecco’s minimal essential medium 
(DMEM, Sigma-Aldrich), supplemented with 10% fetal 
bovine serum (Sigma-Aldrich) and 1% l-glutamine 
(Sigma-Aldrich). Cells were seeded at 10.000 cells/well 
in 96-well plates and grown to 70% confluence in 5% 
 CO2 at 37  °C, in a NU4500E Water-Jacketed  CO2 Incu-
bator (Nuaire, Plymouth, MN). Subsequently, HeLa cells 
were treated with different concentrations of BS (0.3–
10 mg/mL) and incubated at 37 °C with 5%  CO2 for 24 h. 
Untreated cells were used as control. After incubation, 
110  μL MTT solution in DMEM (final concentration 
EI24(%) = Height of emulsion layer× 100/Total height.
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0.5 mg/mL) was added to each well and the plates incu-
bated for 4 h at 37 °C with 5%  CO2. The formazan crys-
tals formed were dissolved by the addition of isopropanol 
(Sigma-Aldrich). After 15  min, the coloured formazan 
derivative was quantified by optical density (OD) at 
570 nm and the inhibition percent calculated as follows: 
cell viability (%) = [1 − (ODsample/ODcontrol)] × 100.
Anti‑adhesive activity of BS against Candida spp. in HeLa 
cells
The influence of BS on the adhesion of C. albicans 
(strains 1, 2 and 4), C. tropicalis, C. krusei or C. glabrata 
to HeLa cells was determined according to Parolin et al. 
[28]. Briefly, HeLa cells were grown on sterile glass cov-
erslips placed in 6-well culture plates, up to 70% con-
fluence. Three mechanisms of action: competition, 
exclusion and displacement, were investigated. For the 
competition test, 1  mL of Candida suspension [1 × 108 
colony forming units (CFU) C. albicans, C. krusei or C. 
glabrata; and 1 × 107  CFU C. tropicalis] plus different 
concentrations of BS (0.00125–1.25 mg/mL) were added 
to each well and incubated at 37 °C for 1 h. For the exclu-
sion test, the cell monolayers were firstly incubated with 
1 mL of BS solutions (0.00125–1.25 mg/mL) for 1 h, and 
then added with the Candida suspensions for 1 h. For the 
displacement test, the monolayers were incubated first 
with Candida suspensions for 1 h, and then with BS for 
an additional hour. Once the incubation was finished, the 
cells were washed with PBS, fixed with May–Grünwald 
and stained with Giemsa (Sigma-Aldrich). The results 
were determined by optical microscopy (1000×), quan-
tifying the number of Candida bound to HeLa cell. Each 
adhesion test was performed in duplicate, in two inde-
pendent experiments, evaluating the fungal number in 
200 randomly chosen epithelial cells.
Murine experimental model
Animals
Female BALB/c mice of 2-month-old from the inbred 
colony of CERELA (Centro de Referencia para Lactobaci-
los) were employed. Animals were housed and fed ad libi-
tum, and a pseudo-estrous condition was weekly induced 
as previously described [32]. The experiments were inde-
pendently repeated two times, with at least five animals 
for each experimental group and sampling day. The Insti-
tutional Laboratory Animal Care and Use Committee 
of CERELA approved the experimental CRL-BIOT-FB-
2019/1A protocol applied in this work.
Safety studies
Mice were randomly assigned to two experimental 
groups: (a) Control mice: intravaginally (i.va.) inocu-
lated with 20  µL saline once per day for 14  days; (b) 
BS-inoculated mice: i.va. inoculated with 20  µL BS 
(1.25  mg/mL in saline) once per day for 14  days. The 
experimental groups, the inoculation sequence and the 
sampling days are showed in Fig. 1a.
Anti‑Candida activity of BS
Candida albicans 2 strain was employed in the follow-
ing experiments to assess anti-Candida activity of BS, 
and the fungal inoculum was prepared as previously 
described [33].
Mice were randomly assigned to five experimental 
groups: (a) BS, BS-treated mice: i.va. inoculated with 
20 µL BS (1.25 mg/mL) once per day for 7 days, then i.va. 
inoculated with saline, and again i.va. inoculated with BS 
once per day for 7 days; (b) Control, Candida-challenged 
mice: i.va. inoculated with saline once per day for 7 days, 
then i.va. challenged with 20 µL containing 1 × 106 CFU 
Candida, and again i.va. inoculated with saline once 
per day for 7 days; (c) Preventive, BS + Candida-treated 
mice: i.va. inoculated with 20 µL BS (1.25 mg/mL) once 
per day for 7 days, then i.va. challenged with 1 × 106 CFU 
Candida, and i.va. inoculated with saline once per day 
for 7 days; (d) Simultaneous, Candida + BS-treated mice: 
i.va. inoculated with saline once per day for 7 days, then 
i.va. challenged with 1 × 106  CFU Candida, and i.va. 
inoculated with 20  µL BS (1.25  mg/mL) once per day 
for 7  days; and (e) Preventive–simultaneous, BS + Can-
dida + BS-treated mice: i.va. inoculated with 20  µL BS 
(1.25  mg/mL) once per day for 7  days, then i.va. chal-
lenged with 1 × 106 CFU Candida, and again i.va. inocu-
lated with BS once per day for 7 days.
The experimental groups, the inoculation sequence and 
the sampling days of the protocols applied are schema-
tized in Fig. 1b.
Sampling and analytical procedures
Vaginal washings and tissues were obtained according 
to De Gregorio et  al. [32]. Cytology of vaginal washing 
and histology of vaginal tissues were performed with 
May–Grünwald–Giemsa and Hematoxylin–Eosin stains, 
respectively, as previously described [32].
The cultivable bacterial numbers in vaginal washing 
were determined (only in mice from safety protocol) by 
the serial dilution method in the following selective agar 
plates: MRS agar pH 6.4 (Biokar, France), Bile Esculin 
agar (Britania, Buenos Aires, Argentina), Mannitol Salt 
Agar (MSA; Britania) and Mc Conkey agar (Britania), 
to quantify the viable lactic acid bacteria (LAB), ente-
rococci, staphylococci and enterobacteria, respectively, 
from the murine vaginal microbiota. Fungi were not eval-
uated because previous studies showed that bacteria, but 
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Simultaneous group: C. albicans 2 + BS (7 doses)-treated mice
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BS group: BS (14 doses)-treated mice
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Fig. 1 Murine experimental models. a Safety assessment of biosurfactant (BS) from L. crispatus BC1 in the murine vaginal tract. b Preventive, 
simultaneous and preventive–simultaneous effect of BS against C. albicans 2 infection. H: Subcutaneous injection of 0.02 mg β‑Estradiol 17‑valerate 
(↑). Arrow correspond to one intravaginal (i.va.) inoculation of: saline (S, ), BS [20 µL containing 1.25 mg/mL of BS ( )], or C. albicans 2 [20 µL 
containing  106 CFU (C.a., )] into BALB/c mice. Sd ( ): sampling day
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not fungi were isolated from the vaginal autochthonous 
microbiota of BALB/c mice [32–34].
In the different experimental protocols for anti-Can-
dida activity the following evaluations were performed: 
(a) Candida viable cell numbers by serial dilution method 
in Sabouraud glucose agar plates containing 0.05  g/L 
chloramphenicol (Britania) [33]; and (b) average number 
of leukocytes in vaginal smears (stained with May–Grün-
wald–Giemsa) counting on optical microscopy in at least 
5 fields at 400× magnification.
Statistical analysis
Student’s t test was applied to compare emulsification 
properties of BS and Tween 80. Analysis of variance 
(ANOVA) using a general linear model was applied to 
analyse the effect of different BS concentrations on: (a) 
HeLa cell viability, and (b) adhesion of Candida spp. 
to HeLa cells. For in  vivo tests, ANOVA (general linear 
model) was also used to determine the effects of factors 
(experimental group and sampling day) on the number 
of viable Candida and the leukocyte number. Graphic 
evaluation of residual values of the significant ANOVAs 
(P < 0.05) showed a distribution close to normal. Then, a 
Tukey’s test of multiple comparisons was applied, estab-
lishing a P < 0.05 value to determine the significant dif-
ferences between mean values, using Minitab statistical 
software (version 16).
Results
Chemical characterization of BS from L. crispatus BC1
Fourier transformed infrared spectroscopy
BS isolated from L. crispatus BC1 was analysed by FT-IR 
spectroscopy and the obtained spectrum is reported 
in Fig.  2. The peak at 3449  cm−1 was attributed to 
the stretching of N–H bond [26]. The peaks around 
2925 cm−1, 1462 cm−1 and 2855 cm−1 are related to  CH3 
and  CH2 groups, demonstrating the presence of aliphatic 
chains [35]. The absorbance at 2300–2400 cm−1 may be 
due to C=N stretching, while the peak at 1635  cm−1, 
relative to CO–N groups, indicated the presence of pep-
tidic groups in the molecule [36]. The peaks at 1564 cm−1 
and at 1402 cm−1 represented the carbonyl group (C=O) 
of carboxylic acid and C=H stretch [37], respectively. 
Finally, the absorption band at 1089 cm−1 was assigned to 
O–C–O extend vibrations of carboxylic acids [36].
Full scan ESI–MS analysis
BS isolated from L. crispatus BC1 strain was analysed by 
means of a triple quadrupole mass analyser operating in 
ESI+ and ESI− mode. MS full scan spectra were acquired 
in an m/z range between 20 and 2000 by direct infusion of 
BS solutions at the concentration of 10 µg/mL in  H2O, as 
such and following a mild basic and acid hydrolysis. Pure 
 H2O was chosen as solvent for analysis, since the freeze-
dried isolated BS powder showed poor solubility in meth-
anol, acetonitrile and mixtures thereof. Acidification of 
Fig. 2 FT‑IR spectrum of biosurfactant isolated from L. crispatus BC1
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aqueous BS solutions with 0.1% formic acid also gave rise 
to precipitate formation. MS spectra obtained in negative 
ionisation mode showed the absence of significant signals 
within the considered m/z range under any of the tested 
conditions. This suggests the lack of acid functions, typi-
cal of glycolipids (mainly rhamnolipids) which usually 
give rise to signals attributed to negatively charged ions 
in the 200–700  m/z range. Full scan spectra acquired 
in ESI+ mode, on the other hand, showed significant 
signals of increasing intensity as the cone voltage was 
increased (likely due to increased desolvation/ionisation). 
From the acquired spectra, some predominant signals 
were highlighted and tentatively attributed to single-
charge ions ([M+H]+, m/z 1397.8), multiple charge ions 
([M+2H]2+, m/z 700.5) and sodium adducts ([M+Na]+, 
m/z 1419.6). Within the same m/z ranges, minor signals 
were observed with cluster distribution (spaced by mul-
tiples of m/z 14) and tentatively attributable to lipid-like 
portions, thus suggesting to be homologs possessing the 
same amino acids sequence, but different fatty acid car-
bon chains. After the hydrolysis of purified BS with HCl 
in methanol, fatty acid methyl esters were extracted by 
using ethyl acetate and then analysed. From the obtained 
full scan MS signals, the putative identity of the main 
fatty acids has been assigned to β-hydroxytridecanoic 
acid (3-OH-C13), β-hydroxytetradecanoic acid (3-OH-
C14), β-hydroxypentadecanoic acid (3-OH-C15) and 
β-hydroxyhexadecanoic acid (3-OH-C16). Moreover, 
both by increasing cone voltage and by analysing BS 
solutions subjected to mild basic hydrolysis, ion signals 
could be observed in the 50–200 m/z range, compatibly 
with the progressive fragmentation of amino acid por-
tions attributable to tyrosine, serine, proline, glycine and 
arginine.
Surface‑activity determination and critical micelle 
concentration of BS
The surface-active properties of BS mainly depend 
on its CMC value and its ability to lower surface ten-
sion and to stabilize emulsions [38].  BS produced by L. 
crispatus BC1 had the ability to reduce the surface ten-
sion from 63.75 ± 2.48 to 49.57 ± 1.31  dyne/cm under 
the tested concentrations (Fig.  3). Specifically, the sur-
face tension gradually decreased with the increase of 
BS concentration and no further decrease was observed 
beyond BS concentration 2.0  mg/mL. The CMC value, 
calculated by plotting the surface tension as a func-
tion of the logarithm of BS concentration, was equal to 
2.0  mg/mL. Considering that the human vaginal pH 
ranges from less than 4 to greater than 5 [4], the sur-
face tension was also measured at pH ranging from 3 
to 6. No significant difference (P > 0.05) was observed 
between the surface tension values obtained in water 
(53.67 ± 0.58 dyne/cm) and in aqueous solutions at pH 3, 
4 and 5 (data not shown). At pH 6.0, a slightly lower sur-
face tension (50.67 ± 1.15  dyne/cm) with respect to the 
values obtained in water and at pH 3 or 4 (P < 0.05) was 
obtained. These results highlighted the maintenance of 
the surfactant properties over a pH range from 3 to 6 and 























Fig. 3 Surface tension versus biosurfactant (BS) concentration (mg/mL). Data are plotted as mean values of surface tension (dyne/cm) ± standard 
deviation (n = 3)
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Emulsification properties of BS
The emulsification activity of BS was determined against 
olive oil, sunflower oil and wheat germ oil. The maximum 
emulsification activity of BS was 66.0 ± 1.4% for wheat 
germ oil, followed by sunflower oil and olive oil (Fig. 4). 
In all cases, EI24 was higher than 50% and only slightly 
lower (P > 0.05) than that obtained with Tween 80 (used 
as control).
Mucoadhesive properties of BS
Mucoadhesive properties of BS were investigated by 
measuring the turbidity at 650  nm of the mixture BS/
mucin, compared to the turbidity of BS solution and 
mucin supernatant. The mixture of BS and mucin was 
characterized by a higher turbidity with respect to the 
controls, as a consequence of the interaction between 
BS and mucin [26]. Specifically, after 3 h the percentage 
increase of the turbidity was equal to 122 ± 2%.
Cytotoxic effect of BS on HeLa cells
Before studying the potential of BS towards Candida 
adhesion on HeLa cells, we assessed if BS could inter-
fere with cell viability in this cellular model. Thus, HeLa 
cells were treated with different concentrations of BS for 
24 h, and then subjected to MTT reduction assay. Con-
centrations of BS below 2.5 mg/mL did not significantly 
reduce cell viability. For higher BS concentrations, a 
dose-dependent reduction (P < 0.01) was observed. In 
particular, BS at the concentration of 2.5 mg/mL reduced 
cell viability by 15.63%; 5 mg/mL by 22.52%; and 10 mg/
mL decreased viability by 39.43% (Fig. 5).
Anti‑adhesive activity of BS against Candida spp
In order to evaluate the antagonist effect of BS against 
Candida, the influence of different concentrations of BS 
(0.00125–1.25  mg/mL) on the adhesion of C. albicans, 
C. tropicalis, C. krusei and C. glabrata to HeLa cells 
was investigated (Fig. 6) by using exclusion, competition 
and displacement assays. The BS concentrations were 
selected on the basis of the previous experiment, as they 
did not affect HeLa cell proliferation.
The activity of BS against yeast adhesion to HeLa cells 
showed to be Candida strain-specific because different 
results were observed among strains of the same species 
(C. albicans) (Fig. 6a–c), and different species (C. tropi-
calis, C. krusei and C. glabrata) (Fig. 6d–f). At the lowest 
dose of BS (0.00125 mg/mL), for some Candida strains, 
an apparent not-significant enhancement of Candida 
adhesion was observed, probably attributable to experi-
mental variability or to a slight substrate-like effect of 
BS. For higher concentrations of BS, an inhibitory activ-
ity was demonstrated, being BS more effective by exclu-
sion mechanism than by competition and displacement 
mechanisms.
In the exclusion test, a significant reduction of at least 
50% was evidenced in the adhesion of C. albicans, C. 
tropicalis and C. krusei strains to HeLa cells at BS con-
centration of 0.125 mg/mL (Fig. 6a–e). C. albicans 1 and 
2 adhesion was reduced even with lower concentrations 
(0.0125 and 0.00125 mg/mL, respectively) (Fig. 6a, b).
When evaluating the competition mechanism, the 
adhesion of C. albicans 2 and 4 to HeLa cells was signifi-
cantly reduced by at least 50% with 0.0125 and 0.125 mg/
mL BS (Fig. 6b, c). This effect was also evidenced for C. 

















 Tween 80 BS
Fig. 4 Emulsification properties of biosurfactant (BS) from L. 
crispatus BC1. Emulsification index at 24 h (EI24%) of BS and Tween 
80 calculated on different substrates: olive oil, sunflower oil and 
wheat germ oil. Data are plotted as mean values of EI24% ± standard 
























Fig. 5 Viability of cervix epithelial cells (HeLa) in presence of 
biosurfactant (BS) from L. crispatus BC1. Data are plotted as average 
values of cell viability (%) ± standard error. Statistically significant 
differences in mean values of cell viability (%) are indicated by 
different letters (P < 0.05)
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C. krusei with 1.25  mg/mL BS. For C. glabrata, adhe-
sion was decreased with BS concentrations ranging from 
0.0125 to 1.25  mg/mL; however, this reduction was not 
significant compared to control, demonstrating that C. 
glabrata is the most resistant strain/species (Fig. 6f ).
In the displacement test, a significant reduction in the 
adhesion of C. tropicalis and C. krusei to HeLa cells was 
only evidenced in the presence of 0.125 and 1.25 mg/mL 
BS, respectively, compared to their controls. The BS was 
not able to interfere with the adhesion of the other tested 
Candida strains in the displacement protocols.
Studies in murine experimental models
The concentration of 1.25 mg/mL of BS was selected to 
evaluate the anti-Candida activity in a murine experi-
mental model, taking into account that this was the most 
effective dose in reducing Candida adhesion to HeLa 
cells, by the different mechanisms studied.
Safety assay of BS
In order to assess the safety of BS, mice were i.va. inocu-
lated for 14 days for cytological and histological evalua-
tion of the murine vaginal tract. The analysis evidenced 
no adverse effect of BS (Additional file 1: Fig. S1a, b). The 
May–Grünwald–Giemsa-stained vaginal smears revealed 
a vaginal discharge of cornified surface cells with pyk-
notic nucleus or flakes and keratinized cell groups in 
both control and BS-treated mice (Additional file 1: Fig. 
S1a). Also, the characteristics of the vaginal epithelium 
and lamina propria were similar in BS-treated and con-
trol groups at days 7 and 14 post-BS inoculation (Addi-
tional file 1: Fig. S1b).
Effect of BS on cultivable murine vaginal microbiota
The i.va. inoculation of BS did not significantly affect the 
number of viable lactic acid bacteria, enterococci, staphy-
lococci, and enterobacteria, although a decrease in the 
number of viable enterobacteria was observed at day 14 
post-BS inoculation compared to control mice (P > 0.05) 
(Additional file 1: Fig. S1c).
Anti‑Candida activity of BS in mice experimental model
The effect of i.va. administration of BS by preventive, 
simultaneous and preventive–simultaneous protocols 
against i.va. challenge with C. albicans 2 was determined. 
The C. albicans 2 strain was employed in these assays, 
since it was characterised by the lowest adhesion to HeLa 
cells in the presence of BS.
Candida viable cells were enumerated in mice vaginal 
samples obtained from the different BS protocols against 
i.va. C. albicans 2 challenge, but a significant inhibitory 
effect was not observed. However, the lowest C. albicans 
2 viable cell counts were observed in the preventive and 
preventive-simultaneous protocols at all the sampling 
days compared to controls (Fig. 7a).
The cytological and histological studies of the murine 
vaginal tract demonstrated that the challenge with C. 
albicans 2 induced a leukocyte influx at all the sampling 
days (Fig. 7b–d). Notably, this influx was reduced by BS 
treatments at all the sampling days, being this reduction 
significant on day 1 post-C.a. challenge in preventive and 
preventive-simultaneous protocols (Fig. 7b–d).
Discussion
The antibacterial, antifungal and antiviral effect of some 
BS from lactobacilli have previously been reported [8, 15, 
25, 39–43]. Also, another interesting application attrib-
uted to BS from lactic acid bacteria is their use as anti-
adhesive agents to prevent pathogen adhesion to the host 
epithelium and to solid surfaces as biomedical instru-
ments [42–49]. In this context, some authors showed that 
the action of BS from lactobacilli against Candida is most 
likely related to anti-adhesive and anti-biofilm effects 
rather than to antimicrobial activity [43, 45]. However, 
the anti-adhesive properties of BS are frequently deter-
mined in in vitro models on polystyrene plates, although 
the use of plates does not mimic the in  vivo conditions 
of epithelial cells [39, 42, 43, 45]. Moreover, the safety of 
BS must be assessed before its application in humans, 
and in vitro cytotoxicity assays and experimental animal 
models are available [43]. In the present work, a new BS 
was isolated from a vaginal L. crispatus strain, and its 
anti-adhesive effect against Candida spp. were investi-
gated on human epithelial cells and, for the first time, in 
a murine experimental model. Also, the chemical char-
acterization of BS was carried out in order to define the 
structure and/or composition of this biomolecule. The 
employment of a vaginal-derived BS to prevent or treat 
Candida infection in the vaginal environment represents 
the main novelty of this study.
The results of FT-IR analysis demonstrated a non-
homogeneous chemical composition and a lipopeptidic 
(See figure on next page.)
Fig. 6 Interference of biosurfactant (BS) from L. crispatus BC1 with Candida adhesion to HeLa cells. C. albicans 1, 2 and 4 (a–c), C. tropicalis (d) C. 
krusei (e) and C. glabrata (f). Exclusion, competition and displacement mechanisms were studied. The results were expresses as percentages of 
adherent yeasts per HeLa cell and compared to adhesion without BS (control value), taken as 100%. Data are plotted as average values of number 
of Candida/HeLa cells (%) ± standard error. Statistically significant differences in mean values in each test (exclusion, competition, displacement) are 
indicated by different letters (P < 0.05)
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nature of the BS isolated from L. crispatus BC1. Moreo-
ver, BS possesses surface tension property along with a 
CMC value corresponding to 2  mg/mL. This result was 
in agreement with previous reports of BS produced by 
lactobacilli [16, 35, 49] or synthetic surfactant, such as 
sodium dodecyl sulphate (SDS) [50]. In addition, a good 
emulsification property of BS against olive oil, sunflower 
oil and wheat germ oil was demonstrated. As regard to 
the CMC and the emulsification property, similar results 
were also determined in our previous work, where BS 
isolated from L. gasseri BC9 showed a high surface activ-
ity and a CMC value corresponding to 2.5 mg/mL [26].
Even though the biosurfactant was obtained from a 
Generally Recognized As Safe (GRAS) microorganism, in 
the present work we evaluated BS cytotoxicity on human 
epithelial cells and BS turned to be non-cytotoxic at the 
concentration of 1.25 mg/mL. Higher BS concentrations 
significantly decreased cell viability, possibly due to a 
detergent-like effect leading to cell membrane disrup-
tion [35, 51, 52]. Similarly, Ferreira et  al. [53] evaluated 
the cytotoxicity of a BS from L. paracasei using a mouse 
fibroblast cell line and demonstrated that 5 and 10  mg/
mL BS showed cell proliferation values of 97% and 64%, 
respectively, whereas 0.5  mg/mL SDS, a synthetic well 
known surfactant, showed a strong inhibitory effect. 
Sharma et al. [35] have also studied the cytotoxicity of BS 
from L. helveticus on a mouse fibroblast cell line, but the 
results demonstrated 43.3% cell viability at 0.0625 mg/mL 
BS, showing similar toxicity when compared with SDS. 
On the other hand, Chiewpattanaku et al. [24] evaluated 
the cytotoxicity of a BS produced by Exophiala derma-
titidis fungus against tumor cell lines [HeLa and leuke-
mia (U937)] and normal cell lines [African green monkey 
kidney (Vero) and peripheral blood mononuclear cells 
(PBMC)]. The authors reported the anti-proliferative 
activity against HeLa and U937 cell lines [Inhibitory con-
centration 50  (IC50) 0.029  mg/mL and 0.049.85  mg/mL, 
respectively] in a dose-dependent manner and no cyto-
toxicity in normal cells even when high concentrations 
were used. The results obtained in this work indicate that 
1.25 mg/mL BS from L. crispatus BC1 is not cytotoxic to 
HeLa cells.
The therapy and control of infections produced by 
Candida species require strategies combining antifungal 
agents with substances that block the adhesion to host 
cells or medical device surfaces [54]. Biosurfactants can 
adsorb to surfaces, forming a film at the interfaces by 
orienting polar and nonpolar groups according to the 
surface hydrophilicity/hydrophobicity. The interaction 
between BS and a substratum surface alters the hydro-
phobicity, thereby interfering with microbial adhesion 
and desorption processes [55, 56]. Thus, the application 
of BS from lactobacilli could disturb Candida adhesion 
and desorption processes by interfering with hydropho-
bicity [25, 43]. The inhibition potential of BS from L. 
crispatus BC1 on Candida adhesion was assayed on cer-
vix epithelial cells (HeLa) since this cell line represents a 
well-established model to study Lactobacillus/Candida 
adhesion, and, previously, such anti-Candida activity 
was demonstrated for L. crispatus BC1 whole cells on 
the same cellular model [28]. Adhesion assays showed 
that BS from L. crispatus BC1 was able to decrease the 
adhesion of all the Candida strains tested. However, dif-
ferences in the adhesion were evidenced among strains 
of the same species (C. albicans), and of different species 
(C. tropicalis, C. krusei and C. glabrata). In this way, BS 
could induce changes in the cell surface characteristics 
and modify the interface contributing to the inhibition of 
the adherence of yeast to the epithelial cells. In addition, 
the cell surface differences in carbohydrate and protein 
concentrations between the Candida strains could con-
tribute to the modulation of cell adhesion [57].
When evaluating the mechanisms by which the BS 
from L. crispatus BC1 interferes with the adhesion of 
Candida spp. to HeLa cells, the exclusion assay showed 
to be the most effective. In a similar way, Itapary Dos 
Santos et  al. [43] demonstrated that BS isolated from 
Lactobacillus reference strains (L. rhamnosus ATCC 9595 
and L. acidophilus ATCC 4356) and vaginal (L. paraca-
sei 11 and L. gasseri 1) reduced C. albicans adhesion and 
disrupted the biofilm formation on polystyrene plates, 
obtaining better results in pre-incubation assay than in 
co-incubation experiments. Thus, the results suggest the 
potential use of BS from L. crispatus BC1 as a pharma-
ceutical ingredient for the prevention of recurrent VVC, 
because the long-term azole treatment (producing longer 
asymptomatic periods between recurrences) does not 
provide a definitive cure [58, 59].
Fig. 7 Anti‑Candida activity of biosurfactant (BS) from L. crispatus BC1 in a murine experimental model. a C. albicans 2 (C.a.) viable cells and 
b leukocytes in vaginal samples of mice receiving preventive (P), preventive–simultaneous (P–S) or simultaneous (S) intravaginally (i.va.) 
administration of BS against i.va. challenge with C.a. C and BS correspond to mice inoculated only with C.a. and BS, respectively. Data are plotted 
as average values of C.a. viable cell or leukocyte numbers ± standard error. Statistically significant differences between the values of experimental 
groups on the same sampling day are indicated by different letters (P < 0.05). c May Grunwald–Giemsa‑stained vaginal smears and d Hematoxylin–
Eosin‑stained vaginal slides of the different experimental group at day 1 of sampling. Influx of leukocytes in the vaginal washing and lumen of 
C.a.‑challenged mice is indicated with black arrows. Results are representative of two independent experiments
(See figure on next page.)
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In order to corroborate the results obtained from 
in vitro studies and to overcome the limits of the employ-
ment of cervical cells, a murine experimental model 
was employed. In a first step, the i.va. inoculation of 
7 and 14 doses BS did not produce modification in the 
murine vaginal cytology and histology and did not sig-
nificantly affect the number of cultivable bacteria evalu-
ated in vaginal washings. These results suggest that the 
i.va. application of BS (1.25 mg/mL) is safe and does not 
modify the cultivable vaginal microbiota. Similar to the 
present work, analytical methods of cultivation and isola-
tion were widely applied in several laboratory animals in 
order to evaluate their vaginal microbiota [32, 34, 60–62]. 
Taking into account that the cultured-based technique 
used in the present work does not allow the isolation of 
uncultured microorganisms, further studies should be 
carried out by applying molecular methodologies to eval-
uate the effect of BS from L. crispatus BC1 on different 
murine vaginal microbial populations.
As member of the normal human microbiota, C. albi-
cans commonly colonizes the vaginal lumen asympto-
matically [63]. However, symptomatic infection can result 
from exuberant mucosal inflammation that is caused 
primarily by fungal overgrowth in the vagina and sub-
sequent epithelial invasion and production of virulence 
effectors [64]. The yeast-to-hypha switch under morpho-
genesis-inducing conditions (e.g., increases in estrogen, 
elevated vaginal pH, and microbiome disruption) induces 
an augmented recognition by pattern recognition recep-
tors (PRR) on the epithelial surface, increased hyphal bio-
mass, expression of hypha-associated virulence factors 
that activates NLRP3 inflammasome signaling, eliciting 
inflammatory cytokines and chemokines in the vaginal 
epithelium, resulting in initial migration of polymor-
phonuclear leukocytes (PMNs) from the lamina propria 
to the vaginal lumen. The failure to adequately reduce 
immunopathological triggers results in the continued 
expression of innate immune effectors by the vaginal 
epithelium. These initial signals, coupled with the sec-
ondary amplification of immune effectors by recruited 
PMNs, contribute to symptomatic infection and char-
acteristic immunopathology [65]. Peters et  al. [66] have 
demonstrated that the depletion of PMNs with neutral-
izing antibodies neither reduced fungal load nor mucosal 
damage levels during infection, suggesting that neutro-
phils are non-protective under such conditions and that 
mucosal damage is mediated by the fungus. Thus, it has 
been suggest that targeting the NLRP3 inflammasome 
during VVC may be a rational therapeutic option for 
disease management [64]. When evaluating the preven-
tive, simultaneous and preventive-simultaneous effect 
of BS against the i.va. challenge with C. albicans 2 in the 
murine experimental model, a significant decrease in 
Candida colonization was not observed with the differ-
ent protocols applied. However, a significant reduction 
in the leukocyte influx induced by the fungus was evi-
denced with the preventive and preventive–simultane-
ous administration of BS (Fig. 7a, b). The ability of the BS 
molecule to interact with mucin could imply an increase 
of the residence time at the application site and, conse-
quently, a longer contact period with the vaginal mucosa 
[67]. Thus, the decrease of the leukocyte influx induced 
by C. albicans 2 strain when preventive and preventive-
simultaneous protocols were applied could be explained 
by the interaction of BS with the mucin secreted by the 
vaginal epithelium, that could delay the contact of the 
fungus with the epithelium. Thus, the results suggest that 
BS preventive application could avoid the mucosal dam-
age mediated by C. albicans during VVC, consequently 
reducing the high levels of inflammatory cytokines in the 
genital tract that could cause mucosal vulnerability and 
increased risk of HIV and sexually transmitted infection 
(STI) acquisition [68].
In the present work a murine model was employed to 
evaluate the host–Candida/BS interactions in the vaginal 
environment. We are aware that there are some differ-
ences between physiology and characteristic of humans 
and our murine model counterpart, such as vaginal pH, 
native microbiota, type and duration of sexual cycle, 
and immune repertoire [69]. In general, low amounts or 
absence of lactobacilli and a neutral pH in murine vagina 
are reported, unlike the high number of lactobacilli and 
low pH, which are characteristics of the human vagina 
[70]. However, given the success of other described vag-
inal disease mouse models [32, 33, 69, 71–73], and our 
findings thus far, we believe this model has useful appli-
cations in studying host–Candida or BS interactions in 
the vaginal environment. To the best of our knowledge, 
the effect of BS isolated from vaginal lactobacilli on Can-
dida albicans in a murine experimental model was not 
reported to date.
Conclusions
In this study, a biosurfactant produced by vaginal L. 
crispatus BC1 was chemically and biologically charac-
terized. The BS presented a non-homogeneous chemi-
cal composition and a lipopeptide nature, a CMC 
value corresponding to 2  mg/mL, and a good emulsi-
fication capability against olive oil, sunflower oil, and 
wheat germ oil. Moreover, BS reduced the Candida 
strains’ ability to adhere to human cervical epithelial 
cells, mainly by exclusion mechanism. Employing a 
murine experimental model, it was evidenced that the 
i.va. inoculation of BS did not affect the vaginal cytol-
ogy, histology and vaginal microbiota (cultivable); but 
reduced the influx the leukocytes induced by the i.va. 
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challenge with C. albicans. This study represents the 
first characterization of BS from vaginal L. crispatus 
BC1 and its potential to interfere with Candida adhe-
sion and the mucosal inflammation mediated by the 
fungus during VVC. However, further studies are 
required to deeply investigate such properties of BS and 
its potential use in humans.
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Additional file 1: Fig. S1. Effect of biosurfactant (BS) from L. crispatus 
BC1 on murine vaginal cytology, histology and microbiota. Photographs 
of (a) May Grunwald–Giemsa‑stained vaginal smears and (b) Hematoxy‑
lin–Eosin‑stained vaginal slides from BALB/c mice intravaginally (i.va.) 
inoculated with 20 µL of saline (control mice) or 20 µL of biosurfactant 
from L. crispatus BC1 (BS, 1.25 mg/mL) (BS‑treated mice), for 7 or 14 days. 
Results are representative of two independent experiments. (c) Viable cells 
of lactic acid bacteria, enterococci, staphylococci and enterobacteria from 
murine vaginal washings (v.w.) of the two experimental groups (BS and 
control) at days 0, 7 and 14 post‑BS inoculation. The data are plotted as 
the mean values of viable cell numbers (Log CFU/mL) ± standard error.
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